Flomax

Boehringer Ingelheim Pharmaceuticals and Abbott Laboratories have announced a collaboration to distribute and co-promote Flomax, Boehringer Ingelheim's drug for the treatment of benign prostatic hyperplasia treatment. The companies plan substantially increased and aggressive promotional efforts for the drug, which had a 30 percent market share in the first half of 1999. Promotional efforts will include a new and ongoing DTC campaign, both television and print, and increased pharmacist education initiatives in a stated effort to achieve 20 percent annual growth for Flomax over the next five years.

Abbott, which currently markets the category leader, Hytrin (terazosin HCl) for BPH, will begin to promote and sell Flomax following the anticipated introduction of a generic terazosin to the U.S. market. Boehringer is hoping to take advantage of Abbott's experience and marketing reach in the BPH category, a market estimated at $500 million.

COPYRIGHT 1999 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group